Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07793461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics

StatusNot Yet Recruiting
PhasePhase 4
Started2027-07
View on ClinicalTrials.gov ↗
The main treatment for Parkinson's disease is a medication called levodopa. Levodopa has to be absorbed from the gut and travel to the brain to work, but a naturally occurring enzyme in the lining of the stomach, called dopamine decarboxylase (AADC), can break some of it down before it ever reaches the brain. We do not yet know whether people whose stomachs have more of this enzyme absorb less of their levodopa dose, have worsened gastrointestinal (GI) symptoms associated with levodopa intake, and whether that affects how well the medication controls their movement symptoms. This research may help doctors understand why levodopa works better in some people with Parkinson's disease than others, which could help improve treatment in future.
Trial Details
NCT Number NCT07793461
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Parkinson's Disease
Enrollment 40 participants
Start Date 2027-07
Primary Completion 2030-07 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-28